Table 1.

Effect of FSK, Glibenclamide and Atorvastatin on body weight, serum glucose, BUN, protein in urine and urine output

Groups	Body Weight (g)	Serum Glucose (mg/dL)	BUN (mg/dL)	Protein in Urine (mg/24 hrs.)	Urine output (mL/24 hrs.)
Normal Control	210.1 ± 14.80	105.8 ± 9.95	19.12 ± 7.47	11.66 ± 2.83	8.42 ± 2.63
FSK per se	215.0 ± 13.80	106.9 ± 10.23	19.93 ± 5.18	11.94 ± 2.31	8.43 ± 2.50
Diabetic Control	328.0 ± 19.03a	360.8 ± 16.90a	102.90 ± 7.39a	85.52 ± 3.33a	76.57 ± 4.61a
FSK-10 in Diabetic group	312.1 ± 18.68a	336.6 ± 17.00a	94.57 ± 6.79a	78.43 ± 4.46a	69.29 ± 4.64a
FSK-20 in Diabetic group	321.0 ± 18.85a	278.6 ± 13.22b	76.89 ± 6.29b	67.69 ± 3.73b	62.29 ± 4.53b
FSK-30 in Diabetic group	315.0 ± 16.83a	203.9 ± 15.03b,c	60.41 ± 6.90b,c	54.16 ± 4.30b,c	50.43 ± 4.72b,c
Glibenclamide in Diabetic group	311.3 ± 19.64a	169.4 ± 12.62b,d	46.84 ± 6.68b,d	43.69 ± 5.42b,d	36.00 ± 3.87b,d
Atorvastatin in Diabetic group	310.6 ± 14.23a	345.0 ± 13.71a	87.85 ± 5.89b	72.53 ± 4.97b	67.14 ± 4.94b
Glibenclamide + FSK-30 in Diabetic group	307.6 ± 12.34a	131.6 ± 9.67b,e	32.08 ± 4.59b,e	32.28 ± 3.96b,e	23.71 ± 4.60b,e
Atorvastatin + FSK-30 in Diabetic group	308.4 ± 12.73a	234.7 ± 17.26b,f	56.63 ± 8.11b,f	56.63 ± 4.94b,f	47.71 ± 3.94b,f

Values are expressed as Mean ± SD (n = 7 per group).

^aP < 0.05 vs normal control, FSK per se group;

^bP < 0.05 vs diabetic control & FSK-10 mg/kg treated group;

^cP < 0.05 vs FSK-20 mg/kg treated group;

^dP < 0.05 vs FSK-30 mg/kg treated group;

^eP < 0.05 vs GB-0.6 mg/kg treated group;

^fP < 0.05 vs Atorvastatin-0.5 mg/kg treated group.